BioNTech (NASDAQ:BNTX) reported quarterly losses of $(2.28) per share which beat the analyst consensus estimate of $(2.52) by 9.52 percent. This is a 25.27 percent decrease over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $138.000 million which missed the analyst consensus estimate of $214.620 million by 35.70 percent. This is a 28.21 percent decrease over sales of $192.233 million the same period last year.